

Ref: EPL/CS/SE/0006/2025

Date: January 24, 2025

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Subject: Intimation for Earnings Call - Q3 FY25

Dear Sir/Madam,

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform that the **Earnings Call for Investors/ Analysts** will be held on **Thursday, February 06, 2025** at **5:30 p.m. (IST)** to discuss the Company's unaudited financial results (standalone and consolidated) and performance for the quarter and nine months ended December 31, 2024.

The details of the aforesaid earnings call for Investors/Analysts is enclosed.

The transcript and the audio recording of the Earnings Call will be made available on the Company's website i.e. www.emcure.com and will be intimated accordingly.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Chetan Sharma
Company Secretary & Compliance Officer
Membership Number: F8352

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251



Emcure Pharmaceuticals Ltd. Q3FY25 Results Earnings Call

Date: Thursday, February 6, 2025

Time: 5:30 pm – 6:30 pm IST

Dial – in Numbers:

Universal Access Number:

+91 22 6280 1220

+91 22 7115 8122

Hong Kong: 800 964 448

Singapore: 800 101 2045

UK: 080 8101 1573

USA: 186 674 62133

[To pre-register online, please click here](#)

For any clarification, please contact:

E-mail: investor.relations@emcure.com